Sept 28 (Reuters) - Merck (MRK.N), opens new tab said on Monday it would pay up to $2.13 billion under a global licensing deal with China's ‌SciBrunch Therapeutics for rights to develop, manufacture ...
The FDA found that the data fell short of the level needed for accelerated approval. (Photo by ISSAM AHMED/AFP via Getty Images) Daiichi Sankyo and Merck & Co. have withdrawn an antibody-drug ...
Sept 25 (Reuters) - Merck (MRK.N), opens new tab and Daiichi Sankyo (4568.T), opens new tab have withdrawn their US application seeking accelerated approval for an experimental lung cancer therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results